IN8bio (NASDAQ:INAB) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of IN8bio (NASDAQ:INAB) in a research note released on Tuesday morning,Benzinga reports. HC Wainwright currently has a $8.00 price objective on the stock.

IN8bio Price Performance

NASDAQ INAB opened at $0.30 on Tuesday. The company has a market cap of $21.47 million, a price-to-earnings ratio of -0.39 and a beta of -0.07. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.84 and a quick ratio of 1.84. The stock’s fifty day moving average price is $0.30 and its 200 day moving average price is $0.63. IN8bio has a 1 year low of $0.22 and a 1 year high of $2.48.

IN8bio (NASDAQ:INAB) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). As a group, equities research analysts forecast that IN8bio will post -0.56 earnings per share for the current year.

Institutional Trading of IN8bio

An institutional investor recently raised its position in IN8bio stock. Sigma Planning Corp boosted its holdings in shares of IN8bio, Inc. (NASDAQ:INAB) by 42.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 851,280 shares of the company’s stock after purchasing an additional 251,600 shares during the period. Sigma Planning Corp owned about 1.82% of IN8bio worth $230,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 92.05% of the company’s stock.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.